KeyCorp Raises LifeStance Health Group (NASDAQ:LFST) Price Target to $13.00

LifeStance Health Group (NASDAQ:LFST) had its price objective boosted by equities research analysts at KeyCorp from $11.00 to $13.00 in a research report issued on Monday,Benzinga reports. The firm presently has an “overweight” rating on the stock. KeyCorp’s price target would suggest a potential upside of 21.50% from the company’s previous close.

LFST has been the topic of several other reports. JPMorgan Chase & Co. increased their price target on LifeStance Health Group from $8.00 to $9.00 and gave the company a “neutral” rating in a report on Thursday, May 14th. Wall Street Zen upgraded LifeStance Health Group from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 4th. Weiss Ratings reissued a “hold (c-)” rating on shares of LifeStance Health Group in a report on Wednesday, May 27th. Zacks Research raised LifeStance Health Group from a “hold” rating to a “strong-buy” rating in a research report on Monday, April 27th. Finally, BTIG Research increased their price objective on shares of LifeStance Health Group from $11.00 to $12.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, LifeStance Health Group has a consensus rating of “Moderate Buy” and a consensus target price of $10.25.

LifeStance Health Group Price Performance

LFST opened at $10.70 on Monday. The company’s 50-day simple moving average is $8.67 and its two-hundred day simple moving average is $7.54. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.48 and a current ratio of 1.48. The stock has a market capitalization of $4.15 billion, a P/E ratio of 178.33 and a beta of 1.12. LifeStance Health Group has a 52-week low of $3.74 and a 52-week high of $11.62.

LifeStance Health Group (NASDAQ:LFST) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.03. LifeStance Health Group had a net margin of 1.55% and a return on equity of 1.56%. The firm had revenue of $403.48 million during the quarter, compared to analyst estimates of $387.46 million. LifeStance Health Group’s quarterly revenue was up 21.2% compared to the same quarter last year. As a group, analysts predict that LifeStance Health Group will post 0.12 EPS for the current year.

Insider Buying and Selling at LifeStance Health Group

In other news, Director Darren M. Black sold 5,899,661 shares of the company’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $8.02, for a total value of $47,315,281.22. Following the completion of the transaction, the director owned 23,310,115 shares of the company’s stock, valued at $186,947,122.30. This represents a 20.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Eric Shuey sold 243,362 shares of the stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $8.02, for a total value of $1,951,763.24. Following the sale, the director owned 867,562 shares of the company’s stock, valued at $6,957,847.24. This represents a 21.91% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 7,762,394 shares of company stock valued at $64,107,859 over the last ninety days. 3.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On LifeStance Health Group

Large investors have recently made changes to their positions in the company. Larson Financial Group LLC grew its holdings in LifeStance Health Group by 19,952.6% during the 4th quarter. Larson Financial Group LLC now owns 3,810 shares of the company’s stock valued at $27,000 after buying an additional 3,791 shares in the last quarter. KBC Group NV bought a new position in shares of LifeStance Health Group during the 1st quarter valued at approximately $29,000. EverSource Wealth Advisors LLC boosted its position in shares of LifeStance Health Group by 359.1% during the 1st quarter. EverSource Wealth Advisors LLC now owns 6,909 shares of the company’s stock valued at $44,000 after acquiring an additional 5,404 shares during the last quarter. Bayesian Capital Management LP purchased a new position in shares of LifeStance Health Group in the second quarter valued at $52,000. Finally, PNC Financial Services Group Inc. grew its holdings in shares of LifeStance Health Group by 615.3% in the first quarter. PNC Financial Services Group Inc. now owns 9,285 shares of the company’s stock valued at $59,000 after purchasing an additional 7,987 shares in the last quarter. 85.50% of the stock is owned by institutional investors.

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.